Repare Therapeutics Inc. (NASDAQ:RPTX) Expected to Post Earnings of -$0.86 Per Share

Equities analysts expect that Repare Therapeutics Inc. (NASDAQ:RPTXGet Rating) will post ($0.86) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Repare Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.80) and the lowest estimate coming in at ($0.91). Repare Therapeutics reported earnings per share of ($0.71) in the same quarter last year, which suggests a negative year-over-year growth rate of 21.1%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Repare Therapeutics will report full year earnings of ($3.37) per share for the current fiscal year, with EPS estimates ranging from ($3.64) to ($2.92). For the next year, analysts anticipate that the company will report earnings of ($3.82) per share, with EPS estimates ranging from ($4.09) to ($3.17). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Repare Therapeutics.

Repare Therapeutics (NASDAQ:RPTXGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.60%.

Several analysts have weighed in on the stock. Piper Sandler boosted their target price on shares of Repare Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and set a $54.00 target price on shares of Repare Therapeutics in a research report on Tuesday, April 12th. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 12th. Stifel Nicolaus cut shares of Repare Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. Finally, The Goldman Sachs Group initiated coverage on shares of Repare Therapeutics in a research note on Thursday, March 17th. They set a “buy” rating and a $43.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $45.13.

Shares of Repare Therapeutics stock opened at $12.09 on Friday. The firm’s 50 day moving average price is $11.10 and its 200-day moving average price is $15.44. Repare Therapeutics has a 52-week low of $8.06 and a 52-week high of $35.75. The company has a market cap of $506.45 million, a P/E ratio of -4.13 and a beta of 0.92.

In related news, major shareholder Bvf Partners L. P/Il purchased 420,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average price of $8.50 per share, with a total value of $3,570,000.00. Following the acquisition, the insider now owns 3,350,950 shares in the company, valued at $28,483,075. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.60% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in RPTX. National Bank of Canada FI purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc grew its holdings in shares of Repare Therapeutics by 55.5% in the fourth quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock valued at $83,000 after purchasing an additional 1,400 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Repare Therapeutics by 9.5% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock valued at $165,000 after buying an additional 1,002 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Repare Therapeutics by 28.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after buying an additional 1,873 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new position in Repare Therapeutics in the third quarter valued at about $198,000. 89.66% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

Further Reading

Get a free copy of the Zacks research report on Repare Therapeutics (RPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repare Therapeutics (NASDAQ:RPTX)

Want More Great Investing Ideas?

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.